Scientists have uncovered a potentially new method to slow the brain damage associated with Alzheimer’s disease. The research indicates that an immune system signaling protein called STING might become overly active in the brain, contributing to memory loss.
Alzheimer’s, the leading cause of dementia, predominantly affects older adults. It gradually destroys brain cells, leading to issues with memory, cognition, communication, and eventually the ability to perform daily activities.
Two key features are commonly seen in the brains of individuals with Alzheimer’s: the accumulation of sticky amyloid plaques and the formation of twisted tau tangles inside neurons. While these are hallmarks of the disease, emerging evidence suggests that ongoing brain inflammation also plays a critical role.
Researchers at the University of Virginia School of Medicine have identified STING as a possible link between this inflammation and the neural damage caused by Alzheimer’s. Normally, STING is part of the body’s innate immune response, helping detect threats like viral infections or internal cell damage. It can trigger inflammation that aids in defending the body and removing cellular debris.
However, excessive immune activity can be destructive. The team found that in Alzheimer’s cases, STING activity becomes abnormally heightened, leading to persistent inflammation that shouldn’t be there. This heightened immune response primarily impacts microglia, the brain’s immune cells. Under typical circumstances, microglia protect brain tissue by clearing waste, damaged cells, and unwanted material.
In Alzheimer’s, though, these cells can become hyperactive, releasing substances that worsen inflammation instead of providing protection. This overreaction may directly contribute to neuronal damage.
To explore this further, the scientists used mouse models of Alzheimer’s disease and blocked STING activity. The results showed a reduction in several markers of harmful brain inflammation. Additionally, decreasing STING activity lessened damage associated with amyloid plaques and tau tangles—two main features of the disease. Interestingly, many experimental treatments focus solely on one of these aspects, but targeting inflammation via STING might address multiple disease mechanisms simultaneously.
The study also found that microglia became less reactive around amyloid deposits, offering better protection to neighboring neurons. Beyond tissue analysis, mice with suppressed STING activity performed better on memory assessments, implying that controlling this immune pathway could help maintain cognitive function.
These findings raise the possibility that drugs targeting STING might serve as future treatments for Alzheimer’s. Such therapies could reduce damaging inflammation while complementing existing approaches aimed directly at plaques or tangles.
However, scientists must exercise caution because STING plays beneficial roles in fighting infections and responding to abnormal cells. Completely blocking it could have negative consequences, so understanding how to modulate this pathway safely in humans is crucial.
Further research is needed to determine whether the benefits observed in mice translate to humans and to ensure that such interventions are safe. Many promising animal studies do not lead to effective human treatments, so rigorous testing is essential.
This work was conducted by researchers at the University of Virginia, including experts affiliated with the Harrison Family Translational Research Center at the Paul and Diane Manning Institute of Biotechnology. The team emphasized the importance of understanding how the immune system’s role in the brain changes with age and disease.
This research reflects a broader shift in Alzheimer’s science, moving beyond the traditional focus on plaques and tangles to exploring how inflammation, immune response, and aging intersect to damage neural tissue. If future studies verify these findings in humans, regulating STING activity could represent a new strategy to protect nerve cells and slow cognitive decline—marking a significant step toward treatments that alter the disease’s course rather than merely managing symptoms.
